Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from CSL ( (AU:CSL) ) is now available.
CSL Limited has announced an update regarding its on-market share buyback program, appointing J.P. Morgan Securities Australia Limited as the broker for the transaction. This strategic move is part of CSL’s ongoing efforts to manage its capital structure effectively, potentially enhancing shareholder value and reinforcing its position in the market.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$282.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited operates in the biotechnology industry, focusing on the development and manufacturing of products for the treatment of serious medical conditions, including blood plasma derivatives and vaccines. The company is a key player in the global healthcare market, providing essential therapies and services.
Average Trading Volume: 997,842
Technical Sentiment Signal: Sell
Current Market Cap: A$101.8B
For detailed information about CSL stock, go to TipRanks’ Stock Analysis page.